or Try an Advanced Search...

    Technical Analysis for MGX - Metagenomi, Inc.

    Grade Last Price % Change Price Change
    C 3.08 1.49% 0.05
    MGX closed up 11.4 percent on Wednesday, January 22, 2025, on 6.48 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Up Up
    Historical MGX trend table...
    Date Alert Name Type % Chg
    20 DMA Resistance Bearish 1.49%
    Crossed Above 50 DMA Bullish 1.49%
    Pocket Pivot Bullish Swing Setup 1.49%
    Volume Surge Other 1.49%
    Wide Range Bar Range Expansion 1.49%
    Wide Bands Range Expansion 1.49%
    Gapped Up Strength 1.49%
    Oversold Stochastic Weakness 1.49%
    Stochastic Buy Signal Bullish 13.05%
    Wide Bands Range Expansion 13.05%
    Older End-of-Day Signals for MGX ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakout 34 minutes ago
    Up 3% 34 minutes ago
    Possible Pocket Pivot about 1 hour ago
    Down 3% about 2 hours ago
    Fell Below Previous Day's Low about 2 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    MGX Chart by TradingView

    Profile

    • Earnings date: Unknown
    Metagenomi, Inc. Description

    Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Molecular Biology Genetic Engineering CRISPR Genome Editing Biological Engineering Gene Editing Human Cancer

    Is MGX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jan 22 People are buying the wrong stock thinking it's part of OpenAI's Stargate Project
    Jan 22 Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
    Jan 16 Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones
    Jan 15 Metagenomi Announces New Appointment to its Board of Directors
    Jan 15 Metagenomi, Inc.'s (NASDAQ:MGX) market cap dropped US$12m last week; individual investors who hold 33% were hit as were institutions
    Jan 8 Metagenomi to Present at the 43rd Annual J.P. Morgan Healthcare Conference
    Dec 11 Metagenomi Presents Highly Specific and Efficient Genome Editing Tools at Nature Conference “RNA at the Bench and Bedside IV”
    Dec 10 Metagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th Annual Meeting
    Dec 8 Jefferies Predicts Up to ~1000% Surge for These 2 ‘Strong Buy’ Stocks
    Nov 18 What Makes Metagenomi (MGX) a New Buy Stock
    See more MGX news...

    Comments

    Indicators

    Indicator Value
    52 Week High 12.74
    52 Week Low 1.62
    Average Volume 2,607,422
    200-Day Moving Average 4.04
    50-Day Moving Average 2.81
    20-Day Moving Average 3.34
    10-Day Moving Average 2.91
    Average True Range 0.41
    RSI (14) 49.24
    ADX 23.66
    +DI 35.81
    -DI 20.15
    Chandelier Exit (Long, 3 ATRs) 3.16
    Chandelier Exit (Short, 3 ATRs) 3.79
    Upper Bollinger Bands 4.29
    Lower Bollinger Band 2.40
    Percent B (%b) 0.34
    BandWidth 56.59
    MACD Line -0.07
    MACD Signal Line 0.03
    MACD Histogram -0.1074
    Fundamentals Value
    Market Cap 113.39 Million
    Num Shares 37.4 Million
    EPS -2.24
    Price-to-Earnings (P/E) Ratio -1.35
    Price-to-Sales 1.77
    Price-to-Book 0.38
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 4.62
    Resistance 3 (R3) 4.77 4.38 4.36
    Resistance 2 (R2) 4.38 3.98 4.31 4.27
    Resistance 1 (R1) 3.71 3.73 3.52 3.56 4.18
    Pivot Point 3.32 3.32 3.23 3.25 3.32
    Support 1 (S1) 2.65 2.92 2.46 2.50 1.88
    Support 2 (S2) 2.26 2.67 2.19 1.79
    Support 3 (S3) 1.59 2.26 1.71
    Support 4 (S4) 1.44